Is COLLEGIUM PHARMACEUTICAL, INC (COLL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 68.8% / 30% | 32.7% / 30% | 17.8% / 30% | 1.45% / 5% | ✗ NOT HALAL |
| DJIM | 68.8% / 33% | 32.7% / 33% | 17.8% / 33% | 1.45% / 5% | ✗ NOT HALAL |
| MSCI | 49.2% / 33% | 23.3% / 33% | 12.8% / 33% | 1.45% / 5% | ✗ NOT HALAL |
| S&P | 68.8% / 33% | 32.7% / 33% | 17.8% / 33% | 1.45% / 5% | ✗ NOT HALAL |
| FTSE | 49.2% / 33% | 23.3% / 33% | 12.8% / 50% | 1.45% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 88.5% | |
| Operating Margin | 30.0% | |
| Net Margin | 8.1% | |
| Return on Equity (ROE) | 23.7% | |
| Return on Assets (ROA) | 7.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $329M |
| Free Cash Flow | $328M |
| Total Debt | $815M |
| Debt-to-Equity | 310.4 |
| Current Ratio | 1.6 |
| Total Assets | $1.7B |
Price & Trading
| Last Close | $33.42 |
| 50-Day MA | $41.93 |
| 200-Day MA | $39.03 |
| Avg Volume | 490K |
| Beta | 0.7 |
|
52-Week Range
$23.23
| |
About COLLEGIUM PHARMACEUTICAL, INC (COLL)
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is COLLEGIUM PHARMACEUTICAL, INC (COLL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), COLLEGIUM PHARMACEUTICAL, INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is COLLEGIUM PHARMACEUTICAL, INC's debt ratio?
COLLEGIUM PHARMACEUTICAL, INC's debt ratio is 68.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 49.2%.
What are COLLEGIUM PHARMACEUTICAL, INC's key financial metrics?
COLLEGIUM PHARMACEUTICAL, INC has a market capitalization of $1.0B, trailing P/E ratio of 18.8, and revenue of $781M. The company maintains a gross margin of 88.5% and a net margin of 8.1%. Return on equity stands at 23.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.